Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Inv. presentation
|
|
PROGENICS PHARMACEUTICALS INC (PGNX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/16/2020 |
GN
| Progenics Stockholders Approve Merger with Lantheus |
| 04/23/2020 |
GN
| Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7 |
| 03/13/2020 |
GN
| PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS |
| 01/16/2020 |
GN
| Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting |
| 12/22/2019 |
GN
| Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd |
| 12/12/2019 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers |
| 12/10/2019 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNX |
| 12/04/2019 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX |
| 11/25/2019 |
GN
| Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting |
| 11/21/2019 |
GN
| Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer |
| 11/08/2019 |
GN
| Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections |
| 11/04/2019 |
GN
| Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan's Nominees Control of the Board |
| 11/01/2019 |
GN
| Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan's Consent Solicitation |
| 10/23/2019 |
GN
| Progenics Highlights Additional Serious Concerns About Velan Capital, L.P. |
| 10/21/2019 |
GN
| Progenics Sends Letter to Shareholders |
| 10/09/2019 |
GN
| Progenics Sends Letter to Shareholders |
| 10/03/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders |
| 10/02/2019 |
GN
| Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PGNX |
| 09/18/2019 |
GN
| Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution |
| 09/03/2019 |
GN
| Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations |
| 07/25/2019 |
GN
| Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis |
| 07/08/2019 |
GN
| Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card |
| 06/28/2019 |
GN
| Progenics Reiterates Targeted Directors' Indispensable Experience and Leadership Critical to the Company's Long-Term Success |
| 06/27/2019 |
GN
| Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital |
| 06/24/2019 |
GN
| Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan's Latest Inaccurate Claims |
| 06/20/2019 |
GN
| Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors |
| 06/19/2019 |
GN
| Progenics to Mail Letter to Shareholders |
| 06/18/2019 |
GN
| Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan |
| 06/13/2019 |
GN
| Progenics to Mail Letter to Shareholders |
| 06/13/2019 |
GN
| Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer |
| 06/06/2019 |
GN
| Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting |
| 06/03/2019 |
GN
| Progenics Pharmaceuticals Mails Letter to Shareholders |
| 05/23/2019 |
GN
| Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting |
| 05/14/2019 |
GN
| Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404 |
|
|
|